logo-loader

Fibrocell Science receives FDA acceptance to review submission for wrinkle treatment

Last updated: 22:36 12 Jan 2011 GMT, First published: 23:36 12 Jan 2011 GMT

no_picture_pai

Biotech company Fibrocell Science (OTCBB: FCSC) announced Wednesday that the US FDA has accepted for review the company's submission for azficel-T, or laViv, a treatment for laugh lines and wrinkles.

The news sent the company's stock price up by more than 21% as of 1:15pm EST on Wednesday, to trade at $0.73.

The company's approach works to replenish the patient's own fibroblasts, the cells that are responsible for releasing collagen, elastin and hyaluronic acid, which add strength and elasticity to the skin.  During the treatment, a patient's own natural fibroblasts are extracted, multiplied and re-injected to regenerate skin.

"We are pleased that our complete response was accepted and look forward to working closely with the FDA through the review process," said chairman and CEO David Pernock.

"If approved, azficel-T will be the first and only personalized cell-based aesthetic treatment."

The company said it is planning to conduct studies on applying its fibroblast technology in additional areas, and for the treatment of restrictive burn scars, acne scars, and periodontal disease.

Fibrocell also recently submitted a clinical study report to the FDA for a Phase II/III trial of azficel-T in acne scarring.

Oriole Resources outlines 2023 achievements and future exploration plans

Oriole Resources PLC (AIM:ORR) CEO Tim Livesey and chief financial officer Bob Smeeton join Proactive's Stephen Gunnion with details of the company's 2023 financial and operational performance. Livesey highlighted successful exploration programs in Cameroon, at the Bibemi and Mbe projects,...

8 minutes ago